The efficacy of anti-tumorigenic agents is often measured through clinical trials, which evaluate:
Tumor Shrinkage: Reduction in tumor size as observed through imaging techniques. Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease without it getting worse. Overall Survival (OS): The length of time from either the date of diagnosis or the start of treatment that patients are still alive. Biomarkers: Changes in specific biological markers that indicate a response to treatment.
